REHOVOT, Israel, Sept. 26, 2019 /PRNewswire/ -- CollPlant
(NASDAQ: CLGN), a regenerative medicine company, today
announced financial results for the second quarter ended
June 30, 2019 and provided an update
on the Company's business developments. Certain metrics, including
those expressed on an adjusted basis, are non-GAAP measures. See
"Use of Non-IFRS (non-GAAP) Measures" below.
CollPlant reported revenues of $606,000 for the second quarter of 2019, an
increase of 232% compared to $182,000
in the second quarter of 2018. The Company ended the second quarter
of 2019 with $1.7 million in cash and
cash equivalents, and received additional funds of $5.5 million in September, through purchase
agreements with certain investors. Comprehensive loss for the
second quarter of 2019 was $1.5
million, or $0.33 per
share.
"During the second quarter of 2019, we continued advancing our
3D bioprinting collaboration with United Therapeutics Corporation
which is using CollPlant's rhCollagen-based BioInk to 3D bioprint
lung scaffolds with the longer-term goal of enabling an unlimited
supply of transplantable lungs for patients with serious medical
conditions," said Yehiel Tal,
CollPlant's Chief Executive Officer. "Furthermore, we are
developing collaborations with leading companies that are
developing 3D bioprinted tissues, and we continue to engage with
large international healthcare companies that seek to implement our
revolutionary technology in their product pipeline."
"The $5.5 million round we
recently received is intended to support the advancement of our
pipeline in the fields of medical aesthetics and 3D bioprinting of
tissues and organs. We are very pleased to have entered into this
transaction with Ami Sagi, who
increased his stake in CollPlant as our largest shareholder, and we
are equally pleased to welcome a new group of U.S. investors who
have deep expertise in 3D printing. Following shareholder approval
of the transaction at a shareholders' meeting scheduled for
October 27, 2019, we expect our
shareholders' equity to be above $2.5
million on such date," stated Mr. Tal.
"We were excited with the development of our second product line
for the medical aesthetics market, 3D bioprinted implants for
breast regeneration. We believe our technology can eliminate the
high risk for adverse events associated with permanent breast
implants by providing a revolutionary alternative that enables the
body to regenerate its own breast tissue. This technology is
already raising interest from leading companies in the breast
implant market," Mr. Tal continued.
"Our dermal filler product line, CollPlant's first product for
the medical aesthetics market, addresses the need for a more
innovative way to treat wrinkles. This product line combines our
proprietary plant-based, tissue regenerating rhCollagen with
hyaluronic acid, a naturally-occurring, moisture-binding compound,
widely used in dermal fillers today," added Mr. Tal.
"CollPlant's revolutionary technology continued to gain
recognition and validation in the scientific and medical
communities. In April, Science Translational Medicine
published a study showing a composite matrix based on CollPlant's
rhCollagen, that led to bone growth superior to the current
standard of care for bone regeneration. In May 2019, CollPlant presented the utilization of
its rhCollagen in the field of 3D bioprinting tissues and organs at
the Annual Meeting of the Tissue Engineering and Regenerative
Medicine International Society (TERMIS) European Union Chapter in
Greece. In June 2019, results from a clinical study
conducted with our VergenixFG advanced wound care product were
presented at the 29th Conference of the European Wound Management
Association. The data demonstrated remarkable wound closure rates
achieved with single application use of VergenixFG," Mr. Tal
concluded.
Second Quarter 2019 Financial Results on IFRS basis
("GAAP")
Revenues for the three months ended June
30, 2019 increased by 232% to $606,000, compared to $182,000 in the second quarter of 2018. Revenues
were derived mainly from CollPlant's BioInk for the development of
3D bioprinting of tissues and life savings organs, of which
$280,000 relates to CollPlant's
license agreement with United Therapeutics, as well as sales of
rhCollagen to CollPlant's collaborator in the development of a
product for the medical aesthetics markets.
The Company's gross profit for the three months ended
June 30, 2019 increased by 33% to
$153,000 compared to $115,000 in the second quarter of 2018.
Total operating costs and expenses for the three months ended
June 30, 2019 were $1.7 million, an increase of 13% compared to
compared to $1.5 million in the
second quarter of 2018. The net increase in the amount of
$200,000 is mainly attributed to in
the development of products for 3D bioprinting and medical
aesthetics market.
Operating loss was for the three months ended June 30, 2019 was $1.6
million, an increase of 14% compared to an operating loss of
$1.4 million in the second quarter of
2018.
Financial income, net for the three months ended June 30, 2019 was $68,000, a decrease of $228,000 compared to financial expenses, net of
$160,000 in the second quarter of
2018. The decrease is mainly due to non-cash re-evaluation expenses
of the CollPlant's warrants and the anti-dilution derivatives.
Comprehensive loss for the second quarter of 2019 was
$1.5 million, or $0.33 per share, compared to a comprehensive loss
of $1.7 million, or $0.36 per share, for the second quarter of
2018.
Cash used in operating activities during the six months ended
June 30, 2019, was $2.5 million compared to $3.3 million in the six months ended June 30, 2018. As of June
30, 2019, cash and cash equivalents totaled $1.7 million.
Cash used in investing activities during the six months ended
June 30, 2019, was $915,000 compared to $646,000 in the six months ended June 30, 2018. The increase is mainly attributed
to the establishment of CollPlant's new headquarters and R&D
center in Rehovot, Israel.
Second Quarter 2019 Financial Results on Non-IFRS Basis
("non-GAAP")
On a non-GAAP basis, the operating costs and expenses for the
second quarter of 2019 were $1.6
million, compared to $1.2 for
the second quarter of 2018. The comprehensive loss for the second
quarter of 2019 was $1.7 million, or
$0.37 per share,
compared to $1.1 million, or
$0.25 per share,
for the second quarter of 2018. Non-GAAP measures exclude certain
non-cash expenses. The table on page 8 includes a reconciliation of
the Company's GAAP results to non-GAAP results. The reconciliation
reflects non-cash net income in the amount of $210,000 with respect to (i) change in fair value
of financial instruments, (ii) share-based compensation to
employees, directors and consultants and (iii) re-measurement of
liability to the IIA.
Use of Non-IFRS ("non-GAAP") Measures
This press release contains certain non-GAAP financial measures
for operating costs and expenses, operating loss, comprehensive
loss and basic and diluted comprehensive loss per share that
exclude the effects of non-cash expense for fair market value
attributed to services received through the Share Purchase
Agreement, remeasurement of liability to the IIA, change in fair
value of financial instruments, and share-based compensation to
employees, directors and consultants. Management believes that
these non-GAAP financial measures provide meaningful supplemental
information regarding the Company's performance that enhances
management's and investors' ability to evaluate the Company's
operating costs, comprehensive loss and loss per share, and to
compare them to historical Company results.
The presentation of this non-GAAP financial information is not
intended to be considered in isolation or as a substitute for the
financial information prepared and presented in accordance with
GAAP. Management uses both GAAP and non-GAAP measures when
operating and evaluating the Company's business internally and
therefore decided to make these non-GAAP adjustments available to
investors. The non-GAAP financial measures used by the Company in
this press release may be different from the measures used by other
companies.
For more information on the non-GAAP financial measures, please
see the "Reconciliation of GAAP to Non-GAAP Financial Measures"
table on page 8 in this press release. This accompanying table on
page 8 has more details on the GAAP financial measures that are
most directly comparable to non-GAAP financial measures and the
related reconciliations between these financial measures.
The Company's consolidated financial results as of, and for the
six months ended June 30, 2019 are
presented in accordance with International Financial Reporting
Standards (IFRS) as issued by the International Accounting
Standards Board (IASB).
About CollPlant
CollPlant is a regenerative medicine company focused on 3D
bioprinting of tissues and organs, and medical aesthetics. Our
products are based on our rhCollagen (recombinant human collagen)
that is produced with CollPlant's proprietary plant based genetic
engineering technology.
Our products address indications for the diverse fields of organ
and tissue repair, and are ushering in a new era in regenerative
medicine. Our flagship rhCollagen BioInk product line is ideal for
3D bioprinting of tissues and organs. In October 2018, we entered into a licensing
agreement with United Therapeutics, whereby United Therapeutics is
using CollPlant's BioInks in the manufacture of 3D bioprinted lungs
for transplant in humans.
For more information about CollPlant, visit
http://www.collplant.com
Safe Harbor Statements
This press release may include forward-looking statements.
Forward-looking statements may include, but are not limited to,
statements relating to CollPlant's objectives plans and strategies,
as well as statements, other than historical facts, that address
activities, events or developments that CollPlant intends, expects,
projects, believes or anticipates will or may occur in the future.
These statements are often characterized by terminology such as
"believes," "hopes," "may," "anticipates," "should," "intends,"
"plans," "will," "expects," "estimates," "projects," "positioned,"
"strategy" and similar expressions and are based on assumptions and
assessments made in light of management's experience and perception
of historical trends, current conditions, expected future
developments and other factors believed to be appropriate.
Forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties that could cause actual
results to differ materially from those expressed or implied in
such statements. Many factors could cause CollPlant's actual
activities or results to differ materially from the activities and
results anticipated in forward-looking statements, including, but
not limited to, the following: the Company's history of significant
losses, its ability to continue as a going concern, and its need to
raise additional capital and its inability to obtain additional
capital on acceptable terms, or at all; the Company's expectations
regarding the timing and cost of commencing clinical trials with
respect to tissues and organs which are based on its rhCollagen
based BioInk, dermal fillers for aesthetics, VergenixSTR, and
VergenixFG; the Company's ability to obtain favorable pre-clinical
and clinical trial results; regulatory action with respect to
rhCollagen based BioInk, dermal fillers for aesthetics,
VergenixSTR, and VergenixFG including but not limited to acceptance
of an application for marketing authorization, review and approval
of such application, and, if approved, the scope of the approved
indication and labeling; commercial success and market acceptance
of the Company's rhCollagen based BioInk, dermal fillers for
aesthetics, VergenixSTR, and VergenixFG; the Company's ability to
establish sales and marketing capabilities or enter into agreements
with third parties and its reliance on third party distributors and
resellers; the Company's ability to establish and maintain
strategic partnerships and other corporate collaborations; the
Company's reliance on third parties to conduct some or all aspects
of its product manufacturing; the scope of protection the Company
is able to establish and maintain for intellectual property rights
and the Company's ability to operate its business without
infringing the intellectual property rights of others; the overall
global economic environment; the impact of competition and new
technologies; general market, political, and economic conditions in
the countries in which the Company operates; projected capital
expenditures and liquidity; changes in the Company's strategy; and
litigation and regulatory proceedings. More detailed information
about the risks and uncertainties affecting CollPlant is contained
under the heading "Risk Factors" included in CollPlant's most
recent annual report on Form 20-F filed with the SEC, and in other
filings that CollPlant has made and may make with the SEC in the
future. The forward-looking statements contained in this press
release are made as of the date of this press release and reflect
CollPlant's current views with respect to future events, and
CollPlant does not undertake and specifically disclaims any
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
COLLPLANT HOLDINGS
LTD.
|
CONDENSED
CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE LOSS
|
(UNAUDITED)
|
|
|
|
Six months
ended
June 30
|
|
|
Three months
ended
June 30
|
|
|
|
2019
|
|
|
2018
|
|
|
2019
|
|
|
2018
|
|
|
|
U.S. dollars in
thousands, except per share data
|
|
Revenue
|
|
|
1,200
|
|
|
|
407
|
|
|
|
606
|
|
|
|
182
|
|
Cost of
Revenue
|
|
|
858
|
|
|
|
92
|
|
|
|
453
|
|
|
|
67
|
|
Gross
Profit
|
|
|
342
|
|
|
|
315
|
|
|
|
153
|
|
|
|
115
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating costs
and expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and
development expenses, net:
|
|
|
1,672
|
|
|
|
1,932
|
|
|
|
797
|
|
|
|
641
|
|
General,
administrative and marketing expenses
|
|
|
1,814
|
|
|
|
1,859
|
|
|
|
944
|
|
|
|
863
|
|
Total operating
costs and expenses:
|
|
|
3,486
|
|
|
|
3,791
|
|
|
|
1,741
|
|
|
|
1,504
|
|
Operating
loss
|
|
|
3,144
|
|
|
|
3,476
|
|
|
|
1,588
|
|
|
|
1,389
|
|
Financial
income
|
|
|
-
|
|
|
|
(25)
|
|
|
|
(325)
|
|
|
|
(47)
|
|
Financial
expenses
|
|
|
237
|
|
|
|
180
|
|
|
|
64
|
|
|
|
247
|
|
Exchange
differences
|
|
|
177
|
|
|
|
11
|
|
|
|
193
|
|
|
|
(40)
|
|
Financial expenses
(income), net
|
|
|
414
|
|
|
|
166
|
|
|
|
(68)
|
|
|
|
160
|
|
Loss for the
period
|
|
|
3,558
|
|
|
|
3,642
|
|
|
|
1,520
|
|
|
|
1,549
|
|
Other
comprehensive loss:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Currency
translation differences
|
|
|
-
|
|
|
|
313
|
|
|
|
-
|
|
|
|
170
|
|
Total
comprehensive loss for the period
|
|
|
3,558
|
|
|
|
3,955
|
|
|
|
1,520
|
|
|
|
1,719
|
|
Basic and diluted
loss per ordinary share
|
|
|
0.76
|
|
|
|
*0.88
|
|
|
|
0.33
|
|
|
|
*0.36
|
|
Weighted average
ordinary shares outstanding
|
|
|
4,660,862
|
|
|
|
*4,137,683
|
|
|
|
4,661,506
|
|
|
|
*4,348,579
|
|
|
|
*After reverse
split
|
COLLPLANT HOLDINGS
LTD.
|
CONDENSED
CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION
|
(UNAUDITED)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
June
30,
|
|
|
December 31,
|
|
|
|
|
|
2019
|
|
|
2018
|
|
|
|
|
|
U.S. dollars in
thousands
|
|
Assets
|
|
|
|
|
Current
assets:
|
|
|
|
|
|
|
|
|
Cash and cash
equivalents
|
|
|
|
|
1,740
|
|
|
|
5,354
|
|
Accounts
receivables:
|
|
|
|
|
|
|
|
|
|
|
Trade
receivables
|
|
|
|
|
611
|
|
|
|
516
|
|
Other
|
|
|
|
|
294
|
|
|
|
334
|
|
Restricted
deposit
|
|
|
|
|
11
|
|
|
|
154
|
|
Inventory
|
|
|
|
|
958
|
|
|
|
814
|
|
|
|
|
|
|
3,614
|
|
|
|
7,172
|
|
Non-current
assets:
|
|
|
|
|
|
|
|
|
|
|
Restricted
deposit
|
|
|
|
|
163
|
|
|
|
155
|
|
Long
term-receivables
|
|
|
|
|
-
|
|
|
|
18
|
|
Right-of-use
assets
|
|
|
|
|
3,215
|
|
|
|
-
|
|
Property and
equipment,
net
|
|
|
|
|
2,239
|
|
|
|
1,407
|
|
Intangible assets,
net
|
|
|
|
|
316
|
|
|
|
340
|
|
|
|
|
|
|
5,933
|
|
|
|
1,920
|
|
TOTAL
ASSETS
|
|
|
|
|
9,547
|
|
|
|
9,092
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities and
equity
|
|
|
|
|
|
Current
liabilities
|
|
|
|
|
|
|
|
|
|
|
Loan
|
|
|
|
|
18
|
|
|
|
22
|
|
Accounts
payable:
|
|
|
|
|
|
|
|
|
|
|
Trade
payables
|
|
|
|
|
761
|
|
|
|
622
|
|
Accrued liabilities
and
other
|
|
|
|
|
679
|
|
|
|
631
|
|
Operating lease
liabilities
|
|
|
|
|
604
|
|
|
|
-
|
|
Contract
liabilities
|
|
|
|
|
1,235
|
|
|
|
970
|
|
|
|
|
|
|
3,297
|
|
|
|
2,245
|
|
Non-current
liabilities
|
|
|
|
|
|
|
|
|
|
|
Warrants at fair
value
|
|
|
|
|
573
|
|
|
|
649
|
|
Derivatives
|
|
|
|
|
327
|
|
|
|
97
|
|
Royalties to the
Israel Innovation Authority
|
|
|
|
|
196
|
|
|
|
316
|
|
Loan
|
|
|
|
|
18
|
|
|
|
22
|
|
Operating lease
liabilities
|
|
|
|
|
3,004
|
|
|
|
-
|
|
Contract
liabilities
|
|
|
|
|
304
|
|
|
|
980
|
|
|
|
|
|
|
4,422
|
|
|
|
2,064
|
|
Total
liabilities
|
|
|
|
|
7,719
|
|
|
|
4,309
|
|
|
|
|
|
|
|
|
|
|
|
|
Commitments and
contingent liabilities
|
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity:
|
|
|
|
|
|
|
|
|
|
|
Ordinary
shares
|
|
|
|
|
1,583
|
|
|
|
1,580
|
|
Additional paid in
capital and warrants
|
|
|
|
|
54,762
|
|
|
|
54,758
|
|
Currency translation
differences
|
|
|
|
|
(1,008)
|
|
|
|
(1,008)
|
|
Accumulated
deficit
|
|
|
|
|
(53,509)
|
|
|
|
(50,547)
|
|
TOTAL
EQUITY
|
|
|
|
|
1,828
|
|
|
|
4,783
|
|
TOTAL LIABILITIES
AND EQUITY
|
|
|
|
|
9,547
|
|
|
|
9,092
|
|
COLLPLANT HOLDINGS
LTD.
|
CONDENSED
CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS
|
(UNAUDITED)
|
|
|
|
Six months ended
June 30,
|
|
|
|
2019
|
|
|
2018
|
|
|
|
U.S. dollars
in thousands
|
|
Cash flows used in
operating activities:
|
|
|
|
|
|
|
Loss for the
period
|
|
|
(3,558)
|
|
|
|
(3,642)
|
|
Adjustments
for:
|
|
|
|
|
|
|
|
|
Depreciation and
amortization
|
|
|
541
|
|
|
|
155
|
|
Share-based
compensation to employees, directors and consultants
|
|
|
596
|
|
|
|
607
|
|
Exchange differences
on cash and cash equivalents
|
|
|
(44)
|
|
|
|
(17)
|
|
Change in fair value
of financial instruments
|
|
|
154
|
|
|
|
725
|
|
Exchange differences
on lease liabilities
|
|
|
298
|
|
|
|
-
|
|
Exchange differences
on restricted
cash
|
|
|
(10)
|
|
|
|
-
|
|
|
|
|
(2,023)
|
|
|
|
(2,172)
|
|
Changes in operating
asset and liability items:
|
|
|
|
|
|
|
|
|
Increase in trade
receivables
|
|
|
(95)
|
|
|
|
(338)
|
|
Increase in
inventory
|
|
|
(144)
|
|
|
|
(467)
|
|
Decrease (increase)
in other receivables (including long-term
receivables)
|
|
|
36
|
|
|
|
(55)
|
|
Increase (decrease)
in trade payables (including long-term
payables)
|
|
|
122
|
|
|
|
(144)
|
|
Increase (decrease)
in accrued liabilities and other payables
|
|
|
91
|
|
|
|
(127)
|
|
Decrease in contract
liabilities (including long-term contract liabilities)
|
|
|
(411)
|
|
|
|
-
|
|
Decrease in royalties
to the IIA, including short term royalties
|
|
|
(118)
|
|
|
|
(32)
|
|
|
|
|
(519)
|
|
|
|
(1,163)
|
|
Net cash used in
operating
activities
|
|
|
(2,542)
|
|
|
|
(3,335)
|
|
|
|
|
|
|
|
|
|
|
Cash flows from
investing activities:
|
|
|
|
|
|
|
|
|
Restricted
deposits
|
|
|
145
|
|
|
|
-
|
|
Purchase of property
and
equipment
|
|
|
(1,090)
|
|
|
|
(646)
|
|
Proceeds from sale of
property and equipment
|
|
|
30
|
|
|
|
-
|
|
Net cash used in
investing activities
|
|
|
(915)
|
|
|
|
(646)
|
|
Cash flows from
financing activities:
|
|
|
|
|
|
|
|
|
Proceeds from
issuance of shares and warrants, less issuance expenses
|
|
|
-
|
|
|
|
1,509
|
|
Loan
received
|
|
|
-
|
|
|
|
60
|
|
Loan paid
|
|
|
(8)
|
|
|
|
-
|
|
Principal elements of
lease payments
|
|
|
(200)
|
|
|
|
(36)
|
|
Exercise of options
into shares
|
|
|
7
|
|
|
|
-
|
|
Net cash provided by
(used in) financing
activities
|
|
|
(201)
|
|
|
|
1,533
|
|
Decrease in cash
and cash
equivalents
|
|
|
(3,658)
|
|
|
|
(2,448)
|
|
Cash and cash
equivalents at the beginning of the period
|
|
|
5,354
|
|
|
|
5,139
|
|
Impact of exchange
rate changes on cash and cash equivalents
|
|
|
44
|
|
|
|
(126)
|
|
Cash and cash
equivalents at the end of the period
|
|
|
1,740
|
|
|
|
2,565
|
|
Appendix to the
statement of cash flows
|
|
|
|
|
|
|
|
|
Non-cash investing
activities:
|
|
|
|
|
|
|
|
|
Conversion of
debentures and pre-paid warrants
|
|
|
-
|
|
|
|
3,739
|
|
CollPlant
Holdings Ltd.
|
Reconciliation of
GAAP to Non-GAAP Financial Measures
|
(Unaudited)
|
|
|
|
|
Six months
ended
June 30
|
|
|
Three months
ended
June 30
|
|
|
|
|
2019
|
|
|
2018
|
|
|
2019
|
|
|
2018
|
|
|
|
|
USD in
thousands
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP
gross profit
|
|
|
|
342
|
|
|
|
315
|
|
|
|
153
|
|
|
|
115
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP operating
costs and expenses:
|
|
|
|
3,486
|
|
|
|
3,791
|
|
|
|
1,741
|
|
|
|
1,504
|
|
Fair market value
attributed to services received through the Alpha
Agreement
|
|
|
|
-
|
|
|
|
442
|
|
|
|
-
|
|
|
|
-
|
|
Remeasurement of
liability to the IIA
|
|
|
|
(125)
|
|
|
|
-
|
|
|
|
(125)
|
|
|
|
-
|
|
Share-based
compensation to employees, directors and consultants
|
|
|
|
596
|
|
|
|
607
|
|
|
|
239
|
|
|
|
282
|
|
Non-GAAP operating
costs and expenses:
|
|
|
|
3,015
|
|
|
|
2,742
|
|
|
|
1,627
|
|
|
|
1,222
|
|
GAAP operating
loss
|
|
|
|
3,144
|
|
|
|
3,476
|
|
|
|
1,588
|
|
|
|
1,389
|
|
Non-GAAP operating
loss
|
|
|
|
2,673
|
|
|
|
2,427
|
|
|
|
1,474
|
|
|
|
1,107
|
|
GAAP Comprehensive
loss
|
|
|
|
3,558
|
|
|
|
3,642
|
|
|
|
1,520
|
|
|
|
1,549
|
|
Fair market value
attributed to services received through the Alpha
Agreement
|
|
|
|
-
|
|
|
|
442
|
|
|
|
-
|
|
|
|
-
|
|
Remeasurement of
liability to the IIA
|
|
|
|
(125)
|
|
|
|
-
|
|
|
|
(125)
|
|
|
|
-
|
|
Change in fair value
of financial instruments
|
|
|
|
108
|
|
|
|
290
|
|
|
|
(324)
|
|
|
|
191
|
|
Share-based
compensation to employees, directors and consultants
|
|
|
|
596
|
|
|
|
607
|
|
|
|
239
|
|
|
|
282
|
|
Non-GAAP
Comprehensive loss
|
|
|
|
2,979
|
|
|
|
2,303
|
|
|
|
1,730
|
|
|
|
1,076
|
|
GAAP Basic and
diluted loss per ordinary share (USD)
|
|
|
|
0.76
|
|
|
|
0.88
|
|
|
|
0.33
|
|
|
|
0.36
|
|
Non-GAAP Basic and diluted loss per ordinary
share (USD)
|
|
|
|
0.64
|
|
|
|
0.56
|
|
|
|
0.37
|
|
|
|
0.25
|
|
Contact at
CollPlant:
|
|
|
|
Eran Rotem
|
|
Deputy CEO &
CFO
|
|
Tel:
+972-73-2325600
|
|
Email:
Eran@collplant.com
|
|
View original
content:http://www.prnewswire.com/news-releases/collplant-reports-second-quarter-2019-financial-results-and-provides-business-update-300925982.html
SOURCE CollPlant